Surface Pharmaceuticals has entered into a definitive stock purchase agreement with an affiliate of Flying L Partners to raise $20 million in Series A financing, according to a press release from Imprimis Pharmaceuticals.
Surface, which is an affiliate of Imprimis, intends to use the funding to advance clinical development of programs focused on ocular surface disease, including dry eye disease treatments, the release said. It will seek FDA approval of three drug candidates for up to five indications.
The funding will allow Surface to be deconsolidated from Imprimis, which means (Read more...)
Uncategorized